Finanzen von Bon Natural Life Ltd (BON)BONBon Natural Life Ltd

Bon Natural Life Ltd (BON) generates its revenue through a diversified portfolio of business segments. Currently, the largest contributor to its top-line growth is Fragrance compounds, accounting for 38.7% of total sales, equivalent to $6.27M. Other significant revenue streams include Bioactive food ingredients and Health supplements (solid drinks). Understanding this composition is critical for investors evaluating how BON navigates market cycles within the Pharmaceuticals industry.

Evaluating the bottom line, Bon Natural Life Ltd maintains a gross margin of 24.00%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at 3.57%, while the net margin is 1.71%. These profitability ratios, combined with a Return on Equity (ROE) of 1.32%, provide a clear picture of how effectively BON converts its operational activities into shareholder value.

In the context of the broader market, BON competes directly with industry leaders such as TRAW and FBLG. With a market capitalization of $9.59M, it holds a significant position in the sector. When comparing efficiency, BON's gross margin of 24.00% stands against TRAW's N/A and FBLG's N/A. Such benchmarking helps identify whether Bon Natural Life Ltd is trading at a premium or discount relative to its financial performance.

The company's financial metrics show a forward P/E of 2.35 and a price-to-sales ratio of 0.62, suggesting that it is trading at a low valuation relative to its sales.